Madam Speaker, I move to suspend the rules and agree to the concurrent resolution (H. Con. Res 357) supporting the goals and ideals of National Cystic Fibrosis Awareness Month. Madam Speaker, I ask unanimous consent that all Members may…
Madam Speaker, I move to suspend the rules and agree to the concurrent resolution (H. Con. Res 357) supporting the goals and ideals of National Cystic Fibrosis Awareness Month.
Madam Speaker, I ask unanimous consent that all Members may have 5 legislative days within which to revise and extend their remarks and insert extraneous material on this resolution.
Madam Speaker, I yield myself such time as I may consume.
Madam Speaker, I rise today in support of H. Con. Res. 357, which supports the goals and ideals of National Cystic Fibrosis Awareness Month, beginning in May. Every year in the United States, about 1,000 children are born with cystic fibrosis, or CF, a life-shortening genetic disease.
According to the Cystic Fibrosis Foundation, those children face a median life expectancy of 36 years, an average that, fortunately, has continued to increase as science and research have developed better treatment and drugs. And while a median life expectancy of 36 is unacceptably low, that figure is cause for hope for those living with the disease and, of course, their families. They know that in 1955, the year parents of children suffering from this disease formed the Cystic Fibrosis Foundation, children born with CF usually did not live to attend preschool. As the life expectancy increases, those suffering with this disease and their families continue to work for a cure or a life-extending treatment.
Madam Speaker, while a cure for cystic fibrosis remains illusive, the symptoms and effects of the disease are fairly simple. CF is one of the most common life-threatening genetic diseases in the United States. More than 30,000 people in the United States have CF, and over half of them are children.
In addition, over 10 million Americans are unknowing, symptom-free carriers of the cystic fibrosis gene. Cystic fibrosis affects the lungs and digestive system.
The defective gene that causes CF triggers the production of abnormally thick mucus in the lungs that leads to restricted breathing, recurring lung infections, and in many cases digestive problems. The infections deteriorate the lungs and their capacity to deliver oxygen to the body, a condition that worsens over time and in many cases even leads to death or the need for a lung transplant. One of the goals of H. Con. Res. 357 is to promote the need for early diagnosis and the importance of newborn screening so that treatment of children with CF can begin as soon as possible to improve their health and longevity.
The five decades that have passed since the founding of the Cystic Fibrosis Foundation have brought not only hope but years to the lives of those suffering from CF. The Cystic Fibrosis Foundation continues to be at the forefront of making more with less in the area of drug discovery and development. The Therapeutics Development Program, TDP, created and launched by the CF Foundation, has pioneered new ways to conduct cutting-edge, lifesaving research in a cost-effective and efficient manner. This program now includes 18 major research institutions across the country in an established clinical trials network. The TDP provides innovative companies with funding, raised through private donations to the CF Foundation, to undertake research and development on promising new drug candidates, and supports an extensive pipeline of potential new therapies. In fact, the CF Foundation currently has more than 30 drugs and therapies in various stages of clinical trials, any one of which could dramatically improve the life of someone suffering from CF. I believe that the innovative programs like the Therapeutics Development Program are part of the blueprint for more efficient and cost-effective health care and should be supported. So, as you can see, Madam Speaker, CF Foundation- sponsored research is adding precious years to the lives of those living with the disease so that they might live long enough to benefit once a cure is found.
Today there is more potential research on new drugs and therapies than funds to finance that lifesaving work. This is a problem created by a wealth of scientific riches, and one that I hope can be bridged by more public-private partnerships which leverage our world-class biotech and pharmaceutical companies with the capabilities of institutions like the National Institutes of Health to ensure that the discovery phase of identifying new drugs and compounds to treat cystic fibrosis continues. To that end the resolution before us today advocates strong partnerships between government resources like the NIH and nonprofits like the Cystic Fibrosis Foundation as a key means to improve care for those with ``orphan'' diseases like CF.
Madam Speaker, in closing, I would like to commend my friend and colleague Mr. Markey from Massachusetts for his leadership and work supporting this resolution and for our partnership cochairing a new Congressional Cystic Fibrosis Caucus. The Congressional Cystic Fibrosis Caucus, like this resolution, is intended to provide Members and the American public a better understanding of cystic fibrosis and the need to support the incredible work that is being done by the Cystic Fibrosis Foundation as well as through public-private collaboration to find a cure.
I would also like to thank all those Members on both sides of the aisle who have cosponsored H. Con. Res. 357 and
those who have joined the Congressional Cystic Fibrosis Caucus. And anyone who is watching is welcome to call my office or Mr. Markey's office. We would like to have your support, and we look forward to it.
So, my colleagues, please join me in honoring and supporting the goals and ideals of National Cystic Fibrosis Awareness Month by simply agreeing to H. Con. Res. 357.
Madam Speaker, I reserve the balance of my time.
Announcement by the Speaker Pro Tempore
Madam Speaker, I have no further requests for time, and I yield back the balance of my time.
Madam Speaker, on that I demand the yeas and nays.